PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Parecoxib in Renal Colic
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT00139646
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Siena, Italy
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 138
- Registration Number
- NCT00139711
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Varses, Italy
Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 137
- Registration Number
- NCT00140036
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Fleurimont, Quebec, Canada
Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 350
- Registration Number
- NCT00139685
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Norfolk, Virginia, United States
A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 330
- Registration Number
- NCT00139672
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3800
- Registration Number
- NCT00138762
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Warminster, Wiltshire, United Kingdom
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2011-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 402
- Registration Number
- NCT00138749
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Pointe-Claire, Quebec, Canada
Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT00139061
- Locations
- ๐ซ๐ท
Pfizer Investigational Site, Tierce, France
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 105
- Registration Number
- NCT00138671
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Neuss, Germany
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00138723
ยฉ Copyright 2024. All Rights Reserved by MedPath